摘要
骨髓增生异常综合征(MDS)是一组髓系恶性克隆性疾病,严重威胁我国人民健康。西医治疗存在自身局限性,中国中医科学院西苑医院率先应用青黄散为主的复方治疗MDS已逾二十载,参与MDS中医病名、病机和治则等中医理论体系的建立,通过多年临床实践发现该治疗方案疗效确切(总有效率达69.40%~93.84%)且不良反应发生率低。并在基础研究中发现青黄散可通过细胞凋亡、表观遗传调控、促进红系分化等多个层面发挥疗效,形成了一套较为完善的青黄散复方安全性评价系统,推动了MDS中西医结合治疗方案的建立。
Myelodysplastic syndrome(MDS)is a group of malignant clone diseases of the myeloid system,which seriously threatens the health of Chinese people.Xiyuan Hospital,China Academy of Chinese Medical Sciences has taken the lead in applying Qinghuang Powder compound to treat MDS for more than 20 years,we has been involved in the establishment of traditional Chinese medicine theoretical system such as the name,pathogenesis and treatment principle of MDS.Through many years of clinical practice,we found that this treatment program has exact efficacy(total effective rate is 69.40%-93.84%)and low incidence of adverse reactions.In addition,it was found in the basic research that Qinghuang Powder can play a role in the efficacy of apoptosis,epigenetic regulation,promoting erythroid differentiation and other aspects,and we also have formed a relatively complete safety evaluation system of Qinghuang Powder compound,and promoting the establishment of integrated traditional Chinese and Western medicine treatment scheme for MDS.
作者
王文儒
丁宇斌
唐旭东
WANG Wen-ru;DING Yu-bin;TANG Xu-dong(Dongfang Hospital,Beijing University of Chinese Medicine,Beijing 100078,China;Xiyuan Hospital,China Academy of Chinese Medical Sciences,Beijing 100091,China;Shenzhen Traditional Chinese Medicine Hospital,Shenzhen 518033,China)
出处
《中华中医药杂志》
CAS
CSCD
北大核心
2023年第6期2757-2761,共5页
China Journal of Traditional Chinese Medicine and Pharmacy
基金
国家自然科学基金面上项目(No.81673819,No.82074258)
中国中医科学院科技创新工程重大攻关项目(No.CI2021A01701)。
关键词
骨髓增生异常综合征
青黄散
基础研究
临床研究
安全评价
Myelodysplastic syndrome
Qinghuang Powder
Basic research
Clinical research
Safety evaluation
